Errol De Souza, PhD


Dr. Errol De Souza is the Executive Chairman of Bionomics Limited, a global, clinical stage biopharmaceutical company developing a pipeline of novel drug candidates targeting ion channels in CNS disorders.  He has substantial experience as an executive in the biopharmaceutical industry, having founded Neurocrine Biosciences and served as president and CEO of several public and

Dr. Errol De Souza is the Executive Chairman of Bionomics Limited, a global, clinical stage biopharmaceutical company developing a pipeline of novel drug candidates targeting ion channels in CNS disorders.  He has substantial experience as an executive in the biopharmaceutical industry, having founded Neurocrine Biosciences and served as president and CEO of several public and private companies including Biodel, Synaptic Pharmaceutical Corp, Neuropore Therapies and Archemix. Dr. De Souza has raised several hundred million dollars in capital in private and public sectors, and has taken companies public as well as sold companies to provide liquidity and build shareholder value. Over Dr. De Souza’s career, he has served in a number of high-ranking research and development (R&D) roles, including as the senior vice president and U.S. head of R&D for Aventis from 1998 to 2002, co-founder and executive vice president of R&D at Neurocrine from 1992 to1998, and head of CNS at DuPont Merck from1990 to 1992. He also serves on the board of directors of several public and private companies.